AUSTRALIANS with type 1 diabetes (T1D) now have access to a device that combines automated insulin delivery with the freedom of a tube-free design.
Insulet Corporation Australia's Omnipod 5 Automated Insulin Delivery System, a tubeless, automated, and waterproof insulin delivery device, has received Therapeutic Goods Administration (TGA) approval.
With over 130,000 Australians living with T1D, and two in three newly diagnosed under the age of 30, this new technology is a significant development, explained the company.
Joanna Sader, General Manager at Insulet, said, "we hear every day how pod therapy has made diabetes a smaller part of people's lives - freeing them from the burden of injections and the intrusiveness of tubes, which is a big reason why people avoid going onto pumps in the first place".
She added research in Australia has demonstrated that people have a preference for pod therapy over both multiple daily injections and tubed pumps, as pods provide better treatment satisfaction.
"The approval of Omnipod 5 Automated Insulin Delivery System by the TGA is an exciting advancement and first of its kind for Australians of all ages living with diabetes, and goes a step further to simplify life with its automated insulin delivery feature," commented Sader.
She added that living with T1D is complex and time-consuming, requiring constant vigilance to manage the condition.
National data shows that access to continuous glucose monitors and pump technologies minimises the risk of complications and emergencies, and has been proven to reduce the mental burden of managing T1D.
However, research also shows accessibility to automated insulin delivery systems remains a challenge due to the current funding model, which excludes most people with T1D from accessing these systems. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jul 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jul 24
